When a parent has cancer: challenges to patients, their families and health providers.

abstract：:Nursing homes are facing increased environmental pressures to improve quality of care. However, this increased emphasis on quality comes at a time when nursing homes are facing revenue constraints as a result of the repeal of the Boren amendment, increased reimbursement based on prospective payment systems and widespr...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Weech-Maldonado R,Mor V,Oluwole A

更新日期：2004-02-01 00:00:00

abstract：:Descemet's stripping endothelial keratoplasty (DSEK) is a relatively new technique that is rapidly replacing full-thickness procedures for those patients needing corneal transplantation for endothelial dysfunction. Benefits of DSEK include a faster recovery, reduced astigmatism, fewer postoperative complications and r...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kharod BV,Carlson AN

更新日期：2007-04-01 00:00:00

abstract：INTRODUCTION:Breast cancer, the second most common cancer in women, exerts a multidimensional grave effect on affected women. Among the several subtypes of breast cancer, the overexpression of the human epidermal growth factor receptor-2 gene is associated with poorer survival and higher relapse rates. Trastuzumab, a m...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Petrou P

更新日期：2019-04-01 00:00:00

abstract：:A comprehensive literature search identified seven instruments, of which three had psychometric data available. These were the 'Sawicki instrument', the Duke Anticoagulation Satisfaction Scale (DASS) and Deep Vein Thrombosis Quality of Life (DVTQoL). Sawicki assessed five domains with acceptable internal reliability. ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wild D,Murray M,Shakespeare A,Reaney M,von Maltzahn R

更新日期：2008-06-01 00:00:00

abstract：:Everybody acknowledges the merits of the European Medicines Evaluation Agency and the progress the European system has permitted in evaluating and approving medicinal products. Nevertheless, the system established in 1995 is ripe for updating and improvement in the light of experience. Some limitations of the procedur...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Garattini S,Bertele' V

更新日期：2002-02-01 00:00:00

abstract：:The incidence of melanoma has been climbing steadily since the early 1970s. Although melanoma can be successfully cured by surgical excision in its early stages, it is the most common fatal form of skin cancer. The most critical factors in determining the prognosis for patients with melanoma are primary tumor thicknes...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Cormier JN,Xing Y,Ross MI,Cantor SB

更新日期：2004-12-01 00:00:00

abstract：OBJECTIVE:To assess changes in the involvement of advisory bodies in the reimbursement decision-making process in Poland, and to evaluate variables that influenced HTA recommendations in the years 2013-2015. RESEARCH DESIGN AND METHODS:Two independent contributors reviewed the statements of the TC, recommendations iss...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kawalec P,Malinowski KP,Trąbka W

更新日期：2018-04-01 00:00:00

abstract：:Most national guidelines for pharmacoeconomic research prescribe discounting, mostly of money and health against the same rate. There is much debate on whether this is adequate. Two theoretical arguments, the consistency argument of Weinstein and Stason, and the paralyzing paradox of Keeler and Cretin, are mostly resp...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Klock RM,Brouwer WB,Annemans LJ,Bos JM,Postma MJ

更新日期：2005-02-01 00:00:00

abstract：:Parkinson's disease (PD) is the second most common neurodegenerative disease. There are no clinical trials comparing all available pharmacological therapies for the treatment of early PD. The objective of this review is to indirectly analyze the efficacy of antiparkinson drugs currently available in Latin America. A s...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Márquez-Cruz M,Díaz-Martínez JP,Soto-Molina H,De Saráchaga AJ,Cervantes-Arriaga A,Llorens-Arenas R,Rodríguez-Violante M

更新日期：2016-01-01 00:00:00

abstract：:Quality-adjusted life-years (QALYs) play an important role in reimbursement decisions when one of the criteria is the cost-effectiveness of the health technology. While for many generic QALYs (e.g., based on the EQ-5D) are viewed as the gold standard, there has been a considerable increase in interest in using conditi...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Petrillo J,Cairns J

更新日期：2008-10-01 00:00:00

abstract：:The primary objective of this review is to develop a conceptual model for Crohn's disease (CD) outlining the disease burden for patients, healthcare systems and wider society, as reported in the scientific literature. A search was conducted using MEDLINE, PsycINFO, EconLit, Health Economic Evaluation Database and Cent...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Gater A,Kitchen H,Heron L,Pollard C,Håkan-Bloch J,Højbjerre L,Hansen BB,Strandberg-Larsen M

更新日期：2015-01-01 00:00:00

abstract：:Growing understanding of the mechanisms and epidemiology of neonatal herpes simplex virus acquisition allows for the development of a new management of the pregnant patient, one that will reduce the risk of transmitting herpes to the newborn. Maternal herpes simplex virus infection, especially acquired during pregnanc...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Baker DA

更新日期：2005-12-01 00:00:00

abstract：:The European Organisation for Research and Treatment of Cancer (EORTC) 50th Anniversary Conference was held on the 15-16 March in Brussels, Belgium. More than 1100 participants (including EORTC members and staff, national research organizations, health authorities, patient advocacy groups, European Commission, cancer ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Bean J,Bottomley A,Meunier F

更新日期：2012-08-01 00:00:00

abstract：AIM:Limitations of vitamin K antagonists (VKAs) include frequent monitoring, dietary restrictions and drug interactions. This study conducted an indepth exploration of perspectives of VKA therapy in respondents with atrial fibrillation or venous thromboembolism. METHODS:A total of 60 respondents, recruited from the UK...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wild D,Murray M,Donatti C

更新日期：2009-10-01 00:00:00

abstract：:Adalimumab is a monoclonal antibody that inhibits TNF, an osteogenic cytokine involved in the pathogenesis of chronic, disabling inflammatory diseases. Adalimumab is indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. It alleviates the symptoms of these diseases, preven...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Gladman DD,Brown RE

更新日期：2008-04-01 00:00:00

abstract：:Recently, the person tradeoff method has received much attention because it directs one to value health improvements of those other than one's self. As a result, several researchers have suggested that the person tradeoff measures preferences in pharmaceutical and health economic analysis more accurately than the stan...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Doctor JN,Miyamoto JM

更新日期：2005-12-01 00:00:00

abstract：:Introduction: Chronic obstructive pulmonary disease (COPD) is the third leading cause of mortality worldwide. The chronic progressive disease is accompanied by a high loss of health-related quality of life (HRQoL). The available drugs usually only have symptomatic effects; therefore, non-pharmacological therapies are ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hindelang M,Kirsch F,Leidl R

更新日期：2020-02-01 00:00:00

abstract：:Economists' approaches to priority setting focus on the principles of opportunity cost, marginal analysis and choice under scarcity. These approaches are based on the premise that it is possible to design a rational priority setting system that will produce legitimate changes in resource allocation. However, beyond is...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Peacock SJ,Mitton C,Ruta D,Donaldson C,Bate A,Hedden L

更新日期：2010-10-01 00:00:00

abstract：INTRODUCTION:There is a lack of knowledge about methods for valuing health intervention-related costs and monetary benefits in the education and criminal justice sectors, also known as 'inter-sectoral costs and benefits' (ICBs). The objective of this study was to develop methods for obtaining unit prices for the valuat...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Drost RM,Paulus AT,Ruwaard D,Evers SM

更新日期：2017-02-01 00:00:00

abstract：INTRODUCTION:This article is part of the series "How to Prepare a Systematic Review (SR) of Economic Evaluations (EE) for Informing Evidence-based Healthcare Decisions" in which a five-step-approach for conducting a SR of EE is proposed. Areas covered: This paper explains the data extraction process, the risk of bias a...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wijnen B,Van Mastrigt G,Redekop WK,Majoie H,De Kinderen R,Evers S

更新日期：2016-12-01 00:00:00

abstract：:Lung cancer is a leading cause of cancer deaths for both men and women across the world. In the past, studies on lung cancer have focused on traditional end points such as survival, disease-free survival or local control. More recently, investigators have begun to appreciate the importance of health-related quality-of...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Siddiqui F,Konski AA,Movsas B

更新日期：2010-12-01 00:00:00

abstract：:This review addresses hidden costs associated with the Bayer VERSANT assay, Roche AMPLICOR MONITOR test and COBAS AMPLICOR MONITOR test and how these influence the final per reportable cost to a testing laboratory in resource-rich and -poor countries. An in-depth evaluation and recommendation of the most cost-effectiv...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Elbeik T,Chen YM,Soutchkov SV,Loftus RA,Beringer S

更新日期：2003-08-01 00:00:00

abstract：:Cancer patient satisfaction assessment is increasingly considered, owing to the need to assess evolving patterns of care organization and delivery or to test new cancer treatments and interventions. This article reviews cancer patient satisfaction questionnaires using key methodological criteria. In total, 17 patient ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Brédart A,Sultan S,Regnault A

更新日期：2010-04-01 00:00:00

abstract：:Given growing interest in multicriteria decision making and multiple cost-effectiveness thresholds' approach, it was decided to investigate its usefulness in Poland. The pricing and reimbursement (P&R) regulations were reviewed and a cross-sectional survey was conducted amongst nurses. The study investigated whether P...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kolasa K

更新日期：2014-10-01 00:00:00

abstract：INTRODUCTION:For optimum results from pharmacological management of overactive bladder, adherence to prescribed medication is required. Overactive bladder treatment has been compromised by low adherence and persistence to medications, losing many people who might benefit from treatment and exposing them to unnecessary ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wagg A

更新日期：2016-08-01 00:00:00

abstract：:The Institute for Quality and Efficiency in Health Care in Germany makes recommendations for ceiling prices of drugs based on an evaluation of the relationship between costs and effects in each therapeutic area. The analysis requires, when applicable, calculation of savings from avoided clinical events and increased f...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Gandjour A,Gafni A

更新日期：2011-08-01 00:00:00

abstract：:In this special report, the economics of prior authorization is examined with a focus on the break-even rate that requests are denied. Using a simple theoretical model, comparative static results are derived and used to consider the cost-effectiveness implications of future changes in prior authorization policies. ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Grant WC,Yoder DM,Mullins CD

更新日期：2004-04-01 00:00:00

abstract：:Skin diseases are among the most common health problems worldwide and are associated with a considerable burden. The burden of skin disease is a multidimensional concept that encompasses psychological, social and financial consequences of the skin disease on the patients, their families and on society. Chronic and inc...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Basra MK,Shahrukh M

更新日期：2009-06-01 00:00:00

abstract：:Alzheimer's disease is a neurodegenerative disorder characterized by cognitive and behavioral deficits. Donepezil and memantine are two medications used to treat the symptoms of cognitive decline in Alzheimer's disease. A modeled cost-effectiveness analysis found that treatment with donepezil to be less costly and mor...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Oremus M,Tarride JE

更新日期：2012-06-01 00:00:00

abstract：:Adenosine and dipyridamole are coronary vasodilators used in nuclear imaging. The acquisition cost of adenosine is four to ten times higher than dipyridamole. Data suggest comparable sensitivity, although specificity may be lower with dipyridamole. While side effect profiles are similar, fewer patients who receive ade...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Reddy P

更新日期：2002-12-01 00:00:00